ZA923310B - Pharmaceutical compositions comprising an anticytokine - Google Patents

Pharmaceutical compositions comprising an anticytokine

Info

Publication number
ZA923310B
ZA923310B ZA923310A ZA923310A ZA923310B ZA 923310 B ZA923310 B ZA 923310B ZA 923310 A ZA923310 A ZA 923310A ZA 923310 A ZA923310 A ZA 923310A ZA 923310 B ZA923310 B ZA 923310B
Authority
ZA
South Africa
Prior art keywords
anticytokine
pharmaceutical compositions
tbps
graft
versus
Prior art date
Application number
ZA923310A
Other languages
English (en)
Inventor
David Wallach
Wallach David
Dan Aderka
Aderka Dan
Hartmut Engelmann
Engelmann Hartmut
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA923310(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of ZA923310B publication Critical patent/ZA923310B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ZA923310A 1991-05-07 1992-05-07 Pharmaceutical compositions comprising an anticytokine ZA923310B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL98078A IL98078A0 (en) 1991-05-07 1991-05-07 Pharmaceutical compositions comprising an anticytokyne

Publications (1)

Publication Number Publication Date
ZA923310B true ZA923310B (en) 1993-01-27

Family

ID=11062415

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA923310A ZA923310B (en) 1991-05-07 1992-05-07 Pharmaceutical compositions comprising an anticytokine

Country Status (12)

Country Link
EP (2) EP0880970B1 (de)
JP (1) JP3320774B2 (de)
AT (2) ATE184488T1 (de)
AU (1) AU1609492A (de)
CA (1) CA2068027C (de)
DE (2) DE69229975T2 (de)
DK (2) DK0512528T3 (de)
ES (2) ES2137935T3 (de)
GR (1) GR3031805T3 (de)
IL (1) IL98078A0 (de)
PT (1) PT880970E (de)
ZA (1) ZA923310B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
JPH09509646A (ja) * 1993-07-30 1997-09-30 ケネディー インスティチュート オブ リューマトロジー 多発性硬化症を治療する方法
HUT76666A (en) * 1994-07-22 1997-10-28 Hoffmann La Roche Pharmaceutical compositions comprising a chimaeric tnf binding protein
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
DE69525181T2 (de) * 1995-07-14 2002-08-14 Applied Research Systems Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CA2273850A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
EP2002846B1 (de) 1996-12-06 2017-01-25 Amgen Inc. Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7674453B2 (en) * 2002-02-06 2010-03-09 Ares Trading Sa Tumor necrosis factor combined with interferon in demyelinating diseases
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
DE69017753T3 (de) * 1989-05-18 2013-06-20 Yeda Research And Development Co., Ltd. Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper
DE69022559T2 (de) * 1989-12-13 1996-05-02 Yeda Res & Dev Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
ATE190629T1 (de) * 1991-01-18 2000-04-15 Amgen Inc Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DK0512528T3 (da) 1999-12-20
JP3320774B2 (ja) 2002-09-03
EP0880970A1 (de) 1998-12-02
CA2068027A1 (en) 1992-11-08
DK0880970T3 (da) 2006-11-20
ES2137935T3 (es) 2000-01-01
GR3031805T3 (en) 2000-02-29
DE69229975T2 (de) 2000-05-11
EP0512528B1 (de) 1999-09-15
ATE334695T1 (de) 2006-08-15
DE69233643D1 (de) 2006-09-14
EP0512528A2 (de) 1992-11-11
DE69233643T2 (de) 2007-07-26
CA2068027C (en) 2003-09-23
EP0880970B1 (de) 2006-08-02
PT880970E (pt) 2006-12-29
EP0512528A3 (en) 1993-07-21
ATE184488T1 (de) 1999-10-15
AU1609492A (en) 1992-11-12
IL98078A0 (en) 1992-06-21
JPH05170661A (ja) 1993-07-09
DE69229975D1 (de) 1999-10-21
ES2270479T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
EP0512528A3 (en) Pharmaceutical compositions comprising an anticytokine
EP0670730A4 (de) Fusionsprotein, das dem rezeptor des tumornekrose-faktors enthält.
EP0168214A3 (en) Tumor necrosis factor, methods for its preparation, compositions containing it, dna encoding it and assay method using such dna
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
GB2158829B (en) Human tumor necrosis factor and dna therefor
AU584608B2 (en) DNA encoding human tumor necrosis factor and human tumor necrosis factor polypeptide
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
IL128407A0 (en) A tumor necrosis factor related ligand
GR3000944T3 (en) Pharmaceutical composition containing thymus extract fractions
PL319040A1 (en) Modified proteins
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
AU1346488A (en) Arginine-depleted human tumor necrosis factor
IL128569A0 (en) Fibroblast growth factor homologous factor S(FHFs) and methods of use
AU7117687A (en) Combination therapy using interleukin-2 and tumor necrosis factor
IL106591A0 (en) An interferon alpha/beta binding protein,its preparation and pharmaceutical compositions containing it
EP0723016A3 (de) Leukocyten-aktivierender Faktor
ZA9010036B (en) Expression of the recombinant tumor necrosis factor binding protein i(tbp-i)
AU2627892A (en) Nuclear inhibitor i-92 and its use for the production of a medicament
AU673835B2 (en) Medicinal composition comprising TCF-II